Background/Aims: The aim of this study was to determine whether expression of P-glycoprotein (P-gp), multidrug-resistance-related protein 1 (MRP1), and lung resistance protein (LRP) was related to the response to induction chemotherapy and prognosis in untreated diffuse large B-cell lymphoma (DLBCL). Methods: We assessed immunohistochemical expression of P-gp, MRP1 and LRP, using formalin-fixed and paraffin-embedded specimens of lymph node in 41 patients with DLBCL. Association between expression of these three proteins and their impact on clinical outcome and prognosis was statistically evaluated. Results: P-gp was positive in 37% of subjects, MRP1 in 63%, and LRP in 68%. The complete remission rates achieved in the group expressing these multidrug resistance (MDR) proteins was significantly lower than in the group not expressing them (20 versus 58%; p = 0.025 in P-gp, 23 versus 80%; p < 0.001 in MRP1 and 32 versus 69%, p = 0.043 in LRP, respectively). Furthermore, the patients expressing LRP had a shorter overall survival rate than those that did not (median of 26 months versus median not reached; p = 0.013). Conclusions: These findings suggest that the three MDR proteins are important predictive factors for the clinical outcome and prognosis in patients with DLBCL.

Khaled HM, Zeri ZK, Mokhtar N, Ali MM, Darwish T, Elatter I, Gaafar R, Moawad MS: A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin’s lymphoma patients: Long-term results. Ann Oncol 1999;10:1489–1492.
Niitsu N, Umeda M: Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma: Comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol 1999;63:337–344.
Campbell C, Sawka C, Franssen E, Berinstein NL: Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin’s lymphoma without G-CSF support. Leuk Lymphoma 1999;35:119–127.
Debenham PG, Kartner N, Siminovitch L, Riordan JR, Ling V: DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol Cell Biol 1992;2:881–889.
Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdedms EW, Baas F, Zamen GJ: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993;60:289–299.
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650–1654.
Jedlitschky G, Lier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucuronate, and sulfate conjugates by MRP gene-encoded conjugate export pump. Cancer Res 1996;56:988–994.
Rappa G, Lorico A, Flavell RA, Sartorelli AC: Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997;57:5232–5237.
Schelfer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein is the human vault protein. Nat Med 1995;1:578–582
Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EAC, Scheper RJ: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12:550–556.
Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer 1996;65:230–237.
Kitazono M, Sumizawa T, Takebayashi Y, Chen Z-S, Furukawa T, Nagayama S, Tani A, Takao S, Aiko T, Akiyama S: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999;91:1647–1653.
Michieli M, Damiani D, Ermacora A, Masolimi P, Raspedeori D, Visani G Scheper RJ, Baccarani M: P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: Biological and clinical implications. Br J Haematol 1999;104:318–335.
Dhooge C, De Moerloose B, Laureys G, Kint J, Ferster A, DeBacquer D, Philippe J, Benoit Y: P-glycoprotein is an independent prognostic factor-predicting relapse in childhood acute lymphoblastic leukemia: Results of a 6-year prospective study. Br J Haematol 1999;105:676–683.
Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yanashiro K, Dosaka-Akita H, Nishimura M: Predictive value of expression of P53, Bcl-2, and lung resistance-related protein for response to chemotherapy in non-small lung cancers. Cancer Sci 2003;94:394–399.
Chan HS, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689–704.
Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, Baccarani M: Immunohistological detection of multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991;19:131–140.
Cheng A-L, Su I-J, Chen Y-C, Lee T-C, Wang C-H: Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993;11:109–115.
Yamguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M: Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351–2356.
Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasortes M, Diebold J, Le Prise P-Y, Fauchet R: CD3–, CD5+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;89:2966–2974.
Jung CK, Lee KY, Kim Y, Han K, Shim SI, Kim BK, Kang CS: Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int 2001;51:355–363.
Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gaji-Peczalska K, Wick MR, Turuo T, Bloomfield: Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992;52:3768–3775.
Liu Q, Ohshima K, Kikuchi M: High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma. Histopathology 2001;38:209–216.
Tulpule A, Sherrod A, Dharmapala D, Yang LL, Espina BM, Sanchez MN, Gill PS, Levine AM: Multidrug resistance (MDR-1) expression in aids-related lymphomas. Leuk Res 2002;26:121–127.
Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, Akiba S, Sumizawa T, Utsunomiya A, Arima T, Akiyama S: Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood 2001;98:1160–1165.
Filipits M, Jaeger U, Simontisch I, Chizzali-Bonfadin C, Heinzl H, Pirker R: Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res 2000;6:3417–3423.
The International Non-Hodgkin’s Lymphoma Prognostic Factor Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987–994.
Cheson BD, Horning SJ, Coiffier B, Ship M, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphoma. J Clin Oncol 1999;17:1244–1253.
Malisius R, Merz H, Heinz B, Gafumbegete E, Koch BU, Feller AC: Constant detection of CD2, CD3, CD4, and CD5 in fixed and paraffin-embedded tissue using the peroxidase-mediated deposition of biotin-tyramide. J Histochem Cytochem 1997;54:1665–1672.
Bittle A, Nap M, Jager W, Cornilli F, Lang N: Immunohistochemical detection of P-glycoprotein on frozen and paraffin-embedded tissue sections of normal and malignant tissues. Anticancer Res 1995;15:1007–1014.
Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Beliën JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Maijer CJLM, de Vries EGE, Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses an advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230–1237.
Zhan Z, Sander VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT, Bates SE: Expression of the multidrug resistance-associated protein gene in refractory lymphoma: Quantitation by a validated polymerase chain assay. Blood 1997;89:3795–3801.
Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SPC: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 1993;53:3221–3225.
Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994;91:8822–8826.
Cole SPC, Sparks KE, Fraser L, Loe DW, Grant CE, Wilson GM, Deeley RG: Pharmacological characterization of multidrug resistant MRP-transfected Human tumor cells. Cancer Res 1994;54:5902–5910.
Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, Grosset JM, Lamy T, Fauchet R, Fardel O: High multidrug resistance protein activity in acute myeloid leukemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002;116:834–838.
Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, Tsukamoto K, Noguchi Y, Isomoto H, Takeshima F, Murase K, Kamihira S, Tomoniaga M, Kohno S: Adult T-cell leukemia cell over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer 1999;82:599–604.
Borg AG, Burgess R, Green LM, Scheper RJ, Yin JAL: P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukemic cells. Br J Haematol 2000;108:48–54.
Schwarzenbach H: Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002;19:87–104.
Komdeur R. Plaat BEC, van der Graaf WTA, Hoekstra HJ, Hollema H, van den Berg E, Zwart N, Scheper RJ, Molenaar WM: Expression of multidrug resistance proteins, P-gp, MRP1, and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 2003;39:909–916.
Filipits M, Pohl G, Stranzl T, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler Lechner K, Pirker R: Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91:1508–1513.
Zurita AJ, Diestra JE, Condom E, García Del Muro X, Scheffer GL, Scheper RJ, Pérez J, Germà-Lluch JR, Izuierdo MA: Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumors. Br J Cancer 2003;88:879–886.
Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackerman J, Konigsberg R, Kaufman H, Gisslinger H, Huber H, Ludwig H, Pirker R: Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999;5:2426–2430.
Nuessler V, Stotzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, Wilmans W: Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemic cell lines. Leukemia 1999;13:1864–1872.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.